Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ADCLEC.syn1 |
| Synonyms | |
| Therapy Description |
ADCLEC.syn1 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting ADGRE2 and a chimeric costimulatory receptor (CCR) targeting CLEC12A (CLL1), which potentially induce tumor cell killing (PMID: 37802054). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADCLEC.syn1 | ADCLEC.syn1 comprises T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting ADGRE2 and a chimeric costimulatory receptor (CCR) targeting CLEC12A (CLL1), which potentially induce tumor cell killing (PMID: 37802054). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05748197 | Phase I | Cyclophosphamide + Fludarabine ADCLEC.syn1 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Recruiting | USA | 0 |